Improved Criteria for the Classification of Titin Variants in Inherited Skeletal Myopathies.


Journal

Journal of neuromuscular diseases
ISSN: 2214-3602
Titre abrégé: J Neuromuscul Dis
Pays: Netherlands
ID NLM: 101649948

Informations de publication

Date de publication:
2020
Historique:
pubmed: 11 2 2020
medline: 18 11 2020
entrez: 11 2 2020
Statut: ppublish

Résumé

Extensive genetic screening results in the identification of thousands of rare variants that are difficult to interpret. Because of its sheer size, rare variants in the titin gene (TTN) are detected frequently in any individual. Unambiguous interpretation of molecular findings is almost impossible in many patients with myopathies or cardiomyopathies. To refine the current classification framework for TTN-associated skeletal muscle disorders and standardize the interpretation of TTN variants. We used the guidelines issued by the American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) to re-analyze TTN genetic findings from our patient cohort. We identified in the classification guidelines three rules that are not applicable to titin-related skeletal muscle disorders; six rules that require disease-/gene-specific adjustments and four rules requiring quantitative thresholds for a proper use. In three cases, the rule strength need to be modified. We suggest adjustments are made to the guidelines. We provide frequency thresholds to facilitate filtering of candidate causative variants and guidance for the use and interpretation of functional data and co-segregation evidence. We expect that the variant classification framework for TTN-related skeletal muscle disorders will be further improved along with a better understanding of these diseases.

Sections du résumé

BACKGROUND BACKGROUND
Extensive genetic screening results in the identification of thousands of rare variants that are difficult to interpret. Because of its sheer size, rare variants in the titin gene (TTN) are detected frequently in any individual. Unambiguous interpretation of molecular findings is almost impossible in many patients with myopathies or cardiomyopathies.
OBJECTIVE OBJECTIVE
To refine the current classification framework for TTN-associated skeletal muscle disorders and standardize the interpretation of TTN variants.
METHODS METHODS
We used the guidelines issued by the American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) to re-analyze TTN genetic findings from our patient cohort.
RESULTS RESULTS
We identified in the classification guidelines three rules that are not applicable to titin-related skeletal muscle disorders; six rules that require disease-/gene-specific adjustments and four rules requiring quantitative thresholds for a proper use. In three cases, the rule strength need to be modified.
CONCLUSIONS CONCLUSIONS
We suggest adjustments are made to the guidelines. We provide frequency thresholds to facilitate filtering of candidate causative variants and guidance for the use and interpretation of functional data and co-segregation evidence. We expect that the variant classification framework for TTN-related skeletal muscle disorders will be further improved along with a better understanding of these diseases.

Identifiants

pubmed: 32039858
pii: JND190423
doi: 10.3233/JND-190423
doi:

Substances chimiques

Connectin 0
TTN protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

153-166

Auteurs

Marco Savarese (M)

Folkhälsan Research Center, Helsinki, Finland.
Department of Medical Genetics, Medicum, University of Helsinki, Helsinki, Finland.

Mridul Johari (M)

Folkhälsan Research Center, Helsinki, Finland.
Department of Medical Genetics, Medicum, University of Helsinki, Helsinki, Finland.

Katherine Johnson (K)

The John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK.

Meharji Arumilli (M)

Folkhälsan Research Center, Helsinki, Finland.
Department of Medical Genetics, Medicum, University of Helsinki, Helsinki, Finland.

Annalaura Torella (A)

Dipartimento di Medicina di Precisione, Universitá degli Studi della Campania "Luigi Vanvitelli", Naples, Italy.
Telethon Institute of Genetics and Medicine, Pozzuoli, Italy.

Ana Töpf (A)

The John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK.

Anna Rubegni (A)

IRCCS Fondazione Stella Maris, Pisa, Italy.

Marius Kuhn (M)

Genetikum, Neu-Ulm, Germany.

Teresa Giugliano (T)

Dipartimento di Medicina di Precisione, Universitá degli Studi della Campania "Luigi Vanvitelli", Naples, Italy.
Telethon Institute of Genetics and Medicine, Pozzuoli, Italy.

Dieter Gläser (D)

Genetikum, Neu-Ulm, Germany.

Fabiana Fattori (F)

Unit for Neuromuscular and Neurodegenerative Disorders, Bambino Gesù Children's Hospital, Rome, Italy.

Rachel Thompson (R)

The John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK.

Sini Penttilä (S)

Neuromuscular Research Center, Department of Genetics, Fimlab Laboratories, Tampere, Finland.

Sara Lehtinen (S)

Neuromuscular Research Center, Department of Genetics, Fimlab Laboratories, Tampere, Finland.

Sara Gibertini (S)

Neuromuscular Diseases and Neuroimmunology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy.

Alessandra Ruggieri (A)

Neuromuscular Diseases and Neuroimmunology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy.
Department of Molecular and Translation Medicine, Unit of Biology and Genetics, University of Brescia, Brescia, Italy.

Marina Mora (M)

Neuromuscular Diseases and Neuroimmunology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy.

Ales Maver (A)

Clinical Institute of Medical Genetics, University Medical Centre Ljubljana, Ljubljana, Slovenia.

Borut Peterlin (B)

Clinical Institute of Medical Genetics, University Medical Centre Ljubljana, Ljubljana, Slovenia.

Ami Mankodi (A)

Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, Unites States.

Hanns Lochmüller (H)

Department of Neuropediatrics and Muscle Disorders, Medical Center - University of Freiburg, Faculty of Medicine, Freiburg, Germany.
Centro Nacional de Análisis Genómico (CNAG-CRG), Center for Genomic Regulation, Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
Children's Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, Canada.
Division of Neurology, Department of Medicine, The Ottawa Hospital, Ottawa, Canada.

Filippo Maria Santorelli (FM)

IRCCS Fondazione Stella Maris, Pisa, Italy.

Benedikt Schoser (B)

Friedrich-Baur-Institut, Neurologische Klinik Ludwig-Maximilians-Universität München, Munich, Germany.

Lenka Fajkusová (L)

Centre of Molecular Biology and Gene Therapy, University Hospital Brno and Masaryk University Brno, Brno, Czech Republic.

Volker Straub (V)

The John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK.

Vincenzo Nigro (V)

Dipartimento di Medicina di Precisione, Universitá degli Studi della Campania "Luigi Vanvitelli", Naples, Italy.
Telethon Institute of Genetics and Medicine, Pozzuoli, Italy.

Peter Hackman (P)

Folkhälsan Research Center, Helsinki, Finland.
Department of Medical Genetics, Medicum, University of Helsinki, Helsinki, Finland.

Bjarne Udd (B)

Folkhälsan Research Center, Helsinki, Finland.
Department of Medical Genetics, Medicum, University of Helsinki, Helsinki, Finland.
Department of Neurology, Vaasa Central Hospital, Vaasa, Finland.
Neuromuscular Research Center, Tampere University and University Hospital, Tampere, Finland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH